The fact that YAP/TAZ mRNA levels did not change significantly in response to modulation of the expression of ACTL6A, indicated that ACTL6A might regulate YAP/TAZ function through protein degradation in glioma cells. The gene discussed is ACTL6A; the disease is central nervous system cancer.